Western Wealth Management LLC Sells 8,292 Shares of Johnson & Johnson (NYSE:JNJ)

Western Wealth Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 22.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,678 shares of the company’s stock after selling 8,292 shares during the quarter. Western Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,467,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Rather & Kittrell Inc. grew its position in shares of Johnson & Johnson by 2.0% in the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after purchasing an additional 58 shares during the last quarter. Capital Square LLC grew its holdings in Johnson & Johnson by 1.4% during the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after purchasing an additional 58 shares in the last quarter. Wagner Wealth Management LLC grew its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after purchasing an additional 59 shares in the last quarter. Chesapeake Wealth Management grew its holdings in Johnson & Johnson by 0.7% during the 2nd quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock worth $1,522,000 after acquiring an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC grew its stake in shares of Johnson & Johnson by 1.2% in the 2nd quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on JNJ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, February 6th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $176.14.

Check Out Our Latest Research Report on JNJ

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $156.76 on Monday. The company’s 50-day moving average is $158.20 and its 200 day moving average is $158.73. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The company has a market capitalization of $377.37 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the prior year, the firm earned $2.35 earnings per share. The company’s revenue was down 9.7% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.